Acceptance of eflornithine (dfmo) abstract for oral presentation at digestive disease week

Minneapolis, april 30, 2024 (globe newswire) -- panbela therapeutics, inc. (otcqb: pbla), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for eflornithine, an inhibitor of polyamine synthesis, has been accepted for an oral presentation at the digestive disease week (ddw) conference, which will be held may 18-21, 2024. the work reflects the company's on-going collaboration with vanderbilt university medical center.
PBLA Ratings Summary
PBLA Quant Ranking